Search   
MSDS  : 2-Naphthacenecarboxamide, 4-alpha-S-(dimethylamino)-1,4,4a-alpha-5,5a-alpha,6,1 1,12a- octahydro-3,5-alpha,10,12,12a-alpha-pentahydroxy-6-al pha-methyl-1,11-dioxo-
CAS  : 564-25-0
SYNONYMS  : * Doxiciclina * alpha-6-Deoxy-5-hydroxytetracycline * alpha-6-Deoxyoxytetracycline * 6-alpha-Deoxy-5-oxytetracycline * Doxycycline * GS-3065 * 5-Hydroxy-alpha-6-deoxytetracycline * Liviatin * Vibramycin
*** CHEMICAL IDENTIFICATION ***

RTECS NUMBER : QI8650000
CHEMICAL NAME : 2-Naphthacenecarboxamide,
4-alpha-S-(dimethylamino)-1,4,4a-alpha-5,5a-alpha,6,1
1,12a-
octahydro-3,5-alpha,10,12,12a-alpha-pentahydroxy-6-al
pha-methyl-1,11-dioxo-
CAS REGISTRY NUMBER : 564-25-0
LAST UPDATED : 199609
DATA ITEMS CITED : 15
MOLECULAR FORMULA : C22-H24-N2-O8
MOLECULAR WEIGHT : 444.48
WISWESSER LINE NOTATION : L E6 C666 BV FV CU GUTTT&J DQ GVZ HQ IN1&1 KQ MQ M1
RQ
COMPOUND DESCRIPTOR : Drug
Mutagen
Reproductive Effector
Human
SYNONYMS/TRADE NAMES :
* Doxiciclina
* alpha-6-Deoxy-5-hydroxytetracycline
* alpha-6-Deoxyoxytetracycline
* 6-alpha-Deoxy-5-oxytetracycline
* Doxycycline
* GS-3065
* 5-Hydroxy-alpha-6-deoxytetracycline
* Liviatin
* Vibramycin

*** HEALTH HAZARD DATA ***

** ACUTE TOXICITY DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Human - woman
DOSE/DURATION : 68 mg/kg/24D-I
TOXIC EFFECTS :
Musculoskeletal - joints
Immunological Including Allergic - other immediate (humoral): urticaria,
allergic rhinitis, serum sickness
Nutritional and Gross Metabolic - body temperature increase
REFERENCE :
PGMJAO Postgraduate Medical Journal. (Blackwell Scientific Pub. Ltd., POB
88, Oxford, UK) V.1- 1925- Volume(issue)/page/year: 67,313,1991

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : >2 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
PBPSDY Pharmacological and Biochemical Properties of Drug Substances.
(American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC
20037) V.1- 1977- Volume(issue)/page/year: 2,305,1979

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 378 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris,
France) V.1- 1946- Volume(issue)/page/year: 23,575,1968

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 228 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
PBPSDY Pharmacological and Biochemical Properties of Drug Substances.
(American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC
20037) V.1- 1977- Volume(issue)/page/year: 2,305,1979

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 1870 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
GICTAL Giornale Italiano di Chemioterapia. Italian Journal of Chemotherapy.
(Edizioni Minerva Medica, Casella Postale 491, I-10126 Turin, Italy) V.1-
1954- Volume(issue)/page/year: 17,276,1970

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 410 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
GICTAL Giornale Italiano di Chemioterapia. Italian Journal of Chemotherapy.
(Edizioni Minerva Medica, Casella Postale 491, I-10126 Turin, Italy) V.1-
1954- Volume(issue)/page/year: 17,276,1970

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 241 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
PBPSDY Pharmacological and Biochemical Properties of Drug Substances.
(American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC
20037) V.1- 1977- Volume(issue)/page/year: 2,305,1979

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Mammal - dog
DOSE/DURATION : >500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
PBPSDY Pharmacological and Biochemical Properties of Drug Substances.
(American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC
20037) V.1- 1977- Volume(issue)/page/year: 2,305,1979

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Mammal - dog
DOSE/DURATION : >100 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
PBPSDY Pharmacological and Biochemical Properties of Drug Substances.
(American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC
20037) V.1- 1977- Volume(issue)/page/year: 2,305,1979

** REPRODUCTIVE DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - mouse
DOSE : 750 mg/kg
SEX/DURATION : female 2 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death,
e.g., stunted fetus)
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 36,219,1986

** MUTATION DATA **

TYPE OF TEST : DNA inhibition
TEST SYSTEM : Human Lymphocyte
DOSE/DURATION : 3750 ug/L
REFERENCE :
BCPHBM British Journal of Clinical Pharmacology. (Blackwell Scientific Pub.
Ltd., POB 88, Oxford, UK) V.1- 1974- Volume(issue)/page/year:
16,127,1983

*** REVIEWS ***

TOXICOLOGY REVIEW
PBPSDY Pharmacological and Biochemical Properties of Drug Substances.
(American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC
20037) V.1- 1977- Volume(issue)/page/year: 2,305,1979

*** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA ***

NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA :
NOHS - National Occupational Hazard Survey (1974)
NOHS Hazard Code - 84744
No. of Facilities: 641 (estimated)
No. of Industries: 1
No. of Occupations: 1
No. of Employees: 1281 (estimated)

NOES - National Occupational Exposure Survey (1983)
NOES Hazard Code - 84744
No. of Facilities: 450 (estimated)
No. of Industries: 1
No. of Occupations: 5
No. of Employees: 22055 (estimated)
No. of Female Employees: 18813 (estimated)

*** STATUS IN U.S. ***

EPA GENETOX PROGRAM 1988, Inconclusive: Sperm morphology-human


*** END OF RECORD ***
Search More   
ALL Chemical Property And Toxicity Analysis PAGES IN THIS GROUP
NAMECAS
Myxovalargin A 82658-75-1
Myxovalargin B 85568-63-4
4-Morpholinepropanamine,N-(5-chloro-2-nitrobenzo(b)thien-3-yl)- 149338-22-7
Myxovalargin C 85568-64-5
Myxovalargin D 85568-65-6
Naematolin 11054-16-3
Nagase (bacillus subtilis) 11054-16-3
Najatoxin 11054-16-3
Named reagents and solutions, cpd 39374-34-0
4a-epi-Nanaomycin B 72691-97-5
Nandina domestica Thunb., stem extractSUBSTANCE DEFINITION :Plant containing berberine-type alkaloidsREFERENCE :YKKZAJ Yakugaku Zasshi. Journal of Pharmacy. (Nippon Yakugakkai, 2-12-15Shibuya, Shibuya-ku, Tokyo 150, Japan) No.1- 1881-Volume(issue)/page/year: 82,726,1962 72691-97-5
Naphth(2,3-a)aceanthrylene 84030-79-5
Naphthacene 92-24-0
4-Morpholinepropanamine,N-(3-chlorophenyl)-2,6-dimethyl-N-4-pyridinyl-,mono(2-hydroxybenzoate) 59235-63-1
2-Naphthacenecarboxamide,N-((4-(amidinoamidino)-1-piperazinyl)methyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-di oxo- 16545-11-2
2-Naphthacenecarboxamide,N-((4-(amidinoamidino)-1-piperazinyl)methyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-diox o-, dihydrochloride 13040-98-7
2-Naphthacenecarboxamide,4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo- 10118-90-8
2-Naphthacenecarboxamide,4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-,(4S-(4-alpha,4a-alpha,5a-alpha,12a-alpha))-,disulfate (1:2) (salt) 10118-90-8
2-Naphthacenecarboxamide,4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-,monohydrochloride 13614-98-7
2-Naphthacenecarboxamide,7-bromo-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10- 12,12a-pentahydroxy-6-methyl-1,11-dioxo- 4572-56-9
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,2,3,4,4a,5,5a,6,11,12a-decahydro-1,11-dioxo-N-(hydroxymethyl)-6-methyl-3,6,10,12,12a-pentahydroxy- 1181-54-0
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,6,10,12,12a-pentahydroxy-1,11-dioxo- 127-33-3
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,6,10,12,12a-pentahydroxy-1,11-dioxo-,monohydrochloride 64-73-3
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo- 57-62-5
4-Morpholinepropanamine,N-(3-chlorophenyl)-beta-methyl-N-4-pyridinyl-, (Z)-2-butenedioate (1:2) 21957-74-4
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 64-72-2
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo- 2013-58-3
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-,(4S-(4-alpha,4a-alpha,5-alpha,5a-alpha,6-beta,12a-alpha))- 79-57-2
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-,calcium salt (1:1),(4S-(4-alpha,4a-alpha,5-alpha,5a-alpha,6-beta,12a-alpha))- 7179-50-2
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12, 12a-hexahydroxy-6-methyl-1,11-dioxo-,disodium deriv., dihydrate 6153-65-7
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 2058-46-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-2,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-,monohydrochloride, mixed with potassium nitrite 2058-46-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-, compd.with sodium nitrite (1:3) 2058-46-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-, sodiumsalt 69766-62-7
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12, 12a-hexahydroxy-6-methyl-1,11-dioxo-,sulfate 64038-91-1
4-Morpholinepropanamine,N-(3-chlorophenyl)-N-4-pyridinyl-,bis(2-hydroxybenzoate) 21928-15-4
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-N-((4-(2-hydroxyethyl)-1-piperazinyl)methyl)-6-methyl-1,11-di oxo- 1110-80-1
2-Naphthacenecarboxamide,4-alpha-S-(dimethylamino)-1,4,4a-alpha-5,5a-alpha,6,11,12a-octahydro-3,5-alpha,10,12,12a-alpha-pentahydroxy-6-alpha-methyl-1,11-dioxo- 564-25-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a- pentahydroxy-6-methyl-1,11-dioxo- 60-54-8
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 10592-13-9
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a- pentahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 64-75-5
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)- 751-97-3
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-, mononitrate (salt) 20685-78-3
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a- pentahydroxy-6-methyl-1,11-dioxo-,(4S-(4-alpha,4a-alpha,5a-alpha,6-beta,12a-alpha))-,compd. with 4-hydroxy-3-methoxybenzenesulfonate (1:1) 20228-26-6
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo- 914-00-1
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a- pentahydroxy-6-methylene-1,11-dioxo-,monohydrochloride 3963-95-9
4-Morpholinepropanamine,N-(3-chlorophenyl)-N-4-pyridinyl-beta,2,6-trimethyl-,mono(2-hydroxybenzoate) 23410-76-6
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-9-(morpholinomethyl)-1,11-dioxo- 67238-91-9
2-Naphthacenecarboxamide,N,N'-(ethylenebis((methylimino)methylene))bis(4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-di oxo- 17910-68-8
2-Naphthacenecarboxamide,1,4,4a,5,12,12a-hexahydro-4-(dimethylamino)-1,12-dioxo-6-methyl- 3,10,11,12a-tetrahydroxy-,(4S-(4-alpha,4a-alpha,12a-alpha))- 1665-56-1

Free MSDS Search ( Providing 250,000+ Material Properties )
Chemcas.com| Ads link:todaystock.net